Shopping Cart
- Remove All
- Your shopping cart is currently empty
Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, suitable for studying solid tumours, head and neck cancer, and colorectal cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $396 | In Stock | |
5 mg | $987 | In Stock | |
10 mg | $1,650 | In Stock | |
25 mg | $2,460 | In Stock | |
50 mg | $3,320 | In Stock |
Description | Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, suitable for studying solid tumours, head and neck cancer, and colorectal cancer. |
Targets&IC50 | 0E19 cells:0.1-0.5 μM, OE33 cells:0.1-0.5 μM, NCI-N87 cells:0.1-0.5 μM |
In vitro | Methods: Duligotuzumab (0.01-25 μM) was used to treat NCI-N87, OE19, and OE33 cells, and cell viability was determined by MTT assay. Results: The IC50 values of duligotuzumab for the above three cell lines ranged from 0.1 to -0.5 μM. [1] |
Alias | RO-5541078, RG7597, RG 7597, MEHD-7945A, MEHD7945A |
Cas No. | 1314238-96-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.